Drug-eluting stents

Optical coherence tomography (OCT)-guided drug-eluting stent implantation improves early strut coverage compared with angiography-guided angioplasty. No difference...

solaci - 14 December, 2018

Coronary disease

AHA 2018 | New-Generation DES Are Similar to Second-Generation DES Beyond Polymer

Sirolimus-eluting stents with biodegradable polymer did not offer better outcomes compared with instant-classic (and undoubtedly valid) everolimus-eluting...

solaci - 30 November, 2018

Coronary disease

TCT 2018 | ABSORB IV: Much Life Left for Bioresorbable Scaffolds

Previous studies have documented higher rates of adverse events with bioresorbable scaffolds (ABSORB) compared with metallic drug-eluting...

solaci - 8 October, 2018

Coronary disease

TCT 2018 | ReCre8 Trial: Permanent Polymer and Zotarolimus vs. Polymer-Free Amphilimus

Polymer-free amphilimus-eluting stents are a novel technology combining sirolimus and long-chained fatty acids. This enhances the uptake...

solaci - 8 October, 2018

Coronary disease

TCT 2018 | BIONYX: Durable Polymer-Coated vs. Ultrathin-Strut, Bioresorbable Polymer-Coated DES

This work, presented at TCT 2018 and published simultaneously in The Lancet, is the first randomized study comparing...

solaci - 8 October, 2018

Outcomes of Contemporary DES in Patients with Diabetes: Do They Render Freedom Obsolete?

Everolimus-Eluting Stents Finally Have a Rival and Not Just a “Non-Inferior” Stent

Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference

Early Strut Coverage and Its Implications for Dual Antiplatelet Therapy

AHA 2018 | New-Generation DES Are Similar to Second-Generation DES Beyond Polymer

TCT 2018 | ABSORB IV: Much Life Left for Bioresorbable Scaffolds

TCT 2018 | ReCre8 Trial: Permanent Polymer and Zotarolimus vs. Polymer-Free Amphilimus

TCT 2018 | BIONYX: Durable Polymer-Coated vs. Ultrathin-Strut, Bioresorbable Polymer-Coated DES

Últimas Noticias

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Is it really necessary to monitor all patients after TAVR?

Is it really necessary to monitor all patients after TAVR?

Noticias Institucionales

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

Accesos